One of the alternative treatments currently considered for patients is inhibition of poly(ADP-ribose) polymerase (PARP), because its sensitivity is linked to isocitrate dehydrogenase (IDH) mutations, which are common in patients with chondrosarcoma [1]. Here, IDH1 is linked to chondrosarcoma.